Ultimate Cardiology education center for researchers
Towards more specific treatment for diabetic dyslipidemia

Diabetic dyslipidemia is characterized by a state of elevated triglycerides, small dense LDL particles, and low HDL cholesterol. The causes of small, dense LDL are disputed.

Read More
AGA CLINICAL PRACTICE UPDATE: EXPERT REVIEW - Treatment of Dyslipidemia in Common Liver Diseases

Statins often (3%) cause benign elevations in serum ALT or AST levels and should not be considered contraindicated in patients with liver disease.

Read More
Prognostic Implications of Dual Platelet Reactivity Testing in Acute Coronary Syndrome

Despite advances in treatment, patients with acute coronary syndrome (ACS) continue to be exposed to both short- and long-term thrombotic events. Even with early invasive management, up to 10% of patients hospitalized for ACS will have a recurrent ischaemic event within 12 months of the index hospitalization. Dual-antiplatelet therapy (DAPT) with aspirin and an adenosine diphosphate receptor (ADP) antagonist (clopidogrel, prasugrel, or ticagrelor) is the cornerstone treatment to prevent intraprocedural thrombotic events and postdischarge ischaemic events in patients with ACS. On-treatment platelet reactivity (PR) testing, which measures in vitro platelet aggregation following treatment with antiplatelet therapy, has been proposed as a means of predicting the risk of thrombotic events in patients treatedwith antiplatelet therapy. We hypothesized that pre- and post-procedural testing for HASPR (high on-ADP receptor antagonist platelet reactivity) and high on-ADP receptor antagonist platelet reactivity will predict IPTE, 30-day and 12-month MACCE, respectively, in patients with ACS on DAPT.

Read More
Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry)

This study evaluates the predictive role of Chronic renal failure (CRF), identied by dierent equations for the glomerular ltration rate estimation, on the occurrence of the composite end point, including both ischemic cardiovascular and major bleeding (major adverse cardiovascular and bleeding events [MACBE]) at 1 year.

Read More